trial

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

NCTId NCT01474395
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 16 (estimated)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2013-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
16 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2012-03
Primary completion
2013-06
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
D-serineSensory Based remediation paradigm

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Columbia UniversityCollaborator

Investigators

1
Joshua T Kantrowitz, MDPrincipal Investigator

Sites

1 total
Orangeburg, United States

Linked catalysts

1
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia — primary completion2013-06

Facts & assertions

4 sourced
Enrollment
16
Phase
PHASE2
Primary Completion Date
2013-06
Status
UNKNOWN
relationships
The graph out of here
drug
D-serine
drug
Sensory Based remediation paradigm
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
Columbia University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Joshua T Kantrowitz, MD
person